Disrupting Chaperone/Myocilin Complexes for Glaucoma
Mutations in myocilin are responsible for as many as 33% of juvenile open-angle glaucoma cases, and myocilin is also mutated in some adult forms of the disease. Dr. Dickey’s team has determined that inhibition of one chaperone can reduce the levels of mutant myocilin and that a second chaperone can protect mutant myocilin in the part of the cell where proteins are made and folded, called the endoplasmic reticulum (ER). When they deplete the levels of the second chaperone protein, mutant myocilin is cleared out of the cell. Thus developing a better understanding of how this second chaperone protein associates with myocilin may lead to new therapeutic strategies to combat glaucoma.
Proteins need to be folded into their proper shape to keep the cell functioning properly. However, there are some mutated proteins that can slip unchecked through the protein-folding machinery to do their damage on the cell. Such is the case with mutant myocilin. In this project, these researchers will determine whether manipulation of the protein-folding machinery can help clear mutant myocilin from the ER, an area that has not been investigated in the past. They will also determine the mechanism through which mutant myocilin is cleared. While associations of myocilin with chaperones have been demonstrated, direct intervention in a model of myocilin accumulation by chaperone manipulation has not been pursued.
Dr. Dickey anticipates that the identification of chaperones that associate with mutant myocilin may make excellent drug targets in the future. This same approach is already being developed in other diseases such as cancer, cystic fibrosis, and Alzheimer's disease. This strategy may work extremely well for glaucoma caused by myocilin mutations since a loss of protein functionality does not seem to be detrimental in humans.
About the Researcher
First published on: July 10, 2012
Last modified on: June 13, 2012